Based on the provided data, the forecasted sales of antiarrhythmic medicine in Finland show a steady increase over the years from 2024 to 2028. In 2023, the sales stood at 5 million US Dollars PPP. The year-on-year variation demonstrates a consistent growth rate, with a 2% increase annually. Specifically, for the past two years, the sales grew by 1.96% from 2023 to 2024 and 1.96% from 2024 to 2025. The Compound Annual Growth Rate (CAGR) over the five-year period from 2024 to 2028 is projected to be approximately 1.96%.
Future trends to watch for include advancements in medical technology, which could enhance the effectiveness and adoption of antiarrhythmic medicines, and potential healthcare policy changes in Finland that could impact funding and availability. Additionally, demographic changes such as an aging population might increase demand for cardiovascular medications, including antiarrhythmics.
